pounds 20m delay to skin product

Wednesday 12 August 1998 00:02 BST

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

A REGULATORY setback over a foot treatment made from babies' foreskins will cost Smith & Nephew pounds 20m over the next two years, the healthcare group revealed yesterday.

The company said that the US regulators' request for more clinical trials would delay the launch of Dermagraft, its artificial skin used to treat diabetic foot ulcers, to 2000 - two years later than expected. Novartis is set to launch a similar product at the end of 1999.

Smith & Nephew reported an 11 per cent fall in interim profits to pounds 72m. The shares fell 4p to 155p.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Stay up to date with notifications from The Independent

Thank you for registering

pounds 20m delay to skin product

Join our commenting forum

Thank you for registering